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The pathophysiology of major depressive disorder (MDD) is not fully understood and the diagnosis is
largely based on history and clinical examination. So far, several lines of preclinical data and a single
imaging study implicate a role for the serotonin1B (5-HT1B) receptor subtype. We sought to study 5-HT1B
receptor binding in brain regions of reported relevance in patients with MDD. Subjects were examined at
the Karolinska Institutet PET centre using positron emission tomography (PET) and the 5-HT1B receptor
selective radioligand [11C]AZ10419369. Ten drug-free patients with recurrent MDD and ten control
subjects matched for age and sex were examined. The main outcome measure was [11C]AZ10419369
binding in brain regions of reported relevance in the pathophysiology of MDD. The [11C]AZ10419369
binding potential was signiﬁcantly lower in the MDD group compared with the healthy control group in
the anterior cingulate cortex (20% between-group difference), the subgenual prefrontal cortex (17% be-
tween-group difference), and in the hippocampus (32% between-group difference). The low anterior
cingulate [11C]AZ10419369 binding potential in patients with recurrent MDD positions 5-HT1B receptor
binding in this region as a putative biomarker for MDD and corroborate a role of the anterior cingulate
cortex and associated areas in the pathophysiology of recurrent MDD.
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is a wealth of studies underlining the importance of the
serotonin system in the pathophysiology and treatment of major
depressive disorder (MDD) (Jans et al., 2007; Lundberg et al., 2012;
Ressler and Nemeroff, 2000). Out of the 14 different serotonin
receptor subtypes (Barnes and Sharp, 1999), the
5-hydroxytryptamine(5-HT)1A and 5-HT1B receptor are the in-
hibitory receptors best characterized and known to modulate
neural transmission via Gi-protein-mediated inhibition of adeny-
late cyclase (Barnes and Sharp, 1999; Hoyer et al., 2002). Due to
the availability of selective radioligands the 5-HT1A receptor is by
far the most studied with regard to its relationship to MDD. Some
(Drevets et al., 2007; Savitz and Drevets, 2013) but not all
(Shrestha et al., 2012) molecular imaging studies have reported
lower 5-HT1A receptor binding in the brain in depressed subjects
when compared with controls.
Whereas the 5-HT1A receptor is a somatodendritic receptor, ther Ireland Ltd. This is an open acces5-HT1B receptor is located to the membrane of preterminal axons
where it functions as a presynaptic autoreceptor on serotonergic
neurons or as a postsynaptic heteroreceptor when located on
GABA or glutamatergic neurons (Riad et al., 2000; Ruf and Bhag-
wagar, 2009). 5-HT1B autoreceptors inhibit the release of serotonin
from the presynaptic bulb (Briley and Moret, 1993). The 5-HT1B
receptors in brain are widely distributed to serotonergic projection
areas, with highest densities found in substantia nigra and globus
pallidus and intermediate binding in neocortex and striatum
(Varnas et al., 2001).
Accumulating evidences imply that the 5-HT1B receptor may be
involved in the pathophysiology of MDD. In animal studies low
5-HT1B receptor mRNA in the dorsal raphe nucleus in rats has been
reported to predispose learned helplessness (Neumaier et al.,
2002), and 5-HT1B receptor binding is low in the hippocampus of
sensitive, maternally-separated rats (Shrestha et al., 2013). In hu-
mans, Huang et al. have reported an association between the
5-HT1B receptor gene polymorphism G861C and MDD (Huang
et al., 2003). Also, lower 5-HT1B mRNA expression in the frontal
cortex and higher in the paraventricular nucleus of hypothalamus
has been demonstrated in suicide victims compared with controls
(Anisman et al., 2008). Finally, in a recent PET-study using thes article under the CC BY-NC-ND license
Table 1
Demographics and experimental conditions.
Control subjects MDD p
Subjects 10 10 –
Age, years 48 (25–70) 48 (24–68) 0.599
Gender 6F, 4M 6F, 4M –
BMI 23.471.8 23.472.3 0.96
Smokers 0 0 –
Total number of MDEsa 0 3.5b –
Injected radioactivity, MBq 385745 372738 0.50
Speciﬁc radioactivity, GBq/μmol 170768 2967122 0.02
Injected mass, μg 1.270.5 0.870.7 0.23
Injected mass, μg/kg body weight 0.012 0.017 0.192
AUC cerebellum, kBq/cm3amin 18.474.6 16.374.8 0.317
Education, years 14.673.45 16.472.18 0.169
a MDE¼Major Depressive Episode. Average from 8 patients.
b Two patients had had more than ﬁve previous MDEs, though the exact
number had not been documented in the records. The groups were compared using
paired t-tests, with two-tailed p-values. AUC¼Area Under Curve.
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(BPND) in the ventral striatum was lower in depressed subjects
when compared with controls (Murrough et al., 2011). In conclu-
sion, there is need for a more detailed mapping of 5-HT1B re-
ceptors in the brain of patients with MDD.
At present two 5-HT1B receptor selective radioligands are
available: [11C]P943 and [11C]AZ10419369 (Gallezot et al., 2010;
Pierson et al., 2008; Zimmer and Le Bars, 2013). The properties of
[11C]AZ10419369 for quantiﬁcation of 5-HT1B receptors are at least
as good as [11C]P943 (KD¼0.4 and Ki¼1.2 nM respectively) (Gal-
lezot et al., 2010; Paterson et al., 2013; Varnas et al., 2011).
[11C]AZ10419369 has recently proven suitable for detailed map-
ping of 5-HT1B receptors in the human brain (Tiger et al., 2014;
Varnas et al., 2011). The reproducibility of [11C]AZ10419369 bind-
ing has been examined in humans, with 5–7% test-retest varia-
bility in cortical regions and 7–14% in subcortical regions (Nord
et al., 2014).
In studies of the neuroanatomy of depression, two brain re-
gions have been more consistently related to MDD than others, the
anterior cingulate cortex and hippocampus. Low blood ﬂow and
metabolism in the anterior cingulate cortex is a replicated ﬁnding
in MDD (Drevets et al., 2002, 1997; Pizzagalli et al., 2004). Reduced
volume of the subgenual part of the anterior cingulate cortex has
been demonstrated in a meta-analysis of volumetric studies (Hajek
et al., 2008). Likewise, low volume has also been reported for the
hippocampus (Kempton et al., 2011), the part of the brain having
the most extensive serotonergic innervations (Berumen et al.,
2012).
The aim of the present study was to use PET and
[11C]AZ10419369 to compare 5-HT1B receptor binding in patients
with recurrent MDD with age and sex-matched controls. The hy-
pothesis was that 5-HT1B receptor binding would be aberrant in
the anterior cingulate cortex, ventral striatum and pallidum in the
depressed subjects.2. Methods
2.1. Subjects
The study was approved by the Regional Ethical Review Board
in Stockholm and by the Radiation safety committee of the Kar-
olinska University Hospital. The patients were originally examined
in a study of the mechanism of action of cognitive behavioral
therapy for MDD (Tiger et al., 2014). All but one patient were re-
cruited through advertisement in a morning paper as previously
described (Tiger et al., 2014). Eleven out of 116 volunteers met the
criteria for participation in the study, and were included after
giving written informed consent. Inclusion criterion was an on-
going untreated moderate major depressive episode within major
depressive disorder (MDD). The exclusion criteria were: bipolar
disorder, organic brain disorder, drug or alcohol abuse, MADRS
(Montgomery Åsberg Depression Rating Scale (Montgomery and
Asberg, 1979)) score below 20 or higher than 35, suicidality (de-
ﬁned as 44 on item 10 in MADRS), age 480 or o20 years, on-
going psychopharmacological treatment (wash out-period41
month) and pregnancy. The most common reason for exclusion
was ongoing medication (n¼70), followed by not having a major
depressive episode of moderate severity within recurrent MDD
(n¼13), somatic disease (n¼9), claustrophobia (n¼4), not eligible
age (n¼4), not giving informed consent (n¼2), not eligible for MRI
(n¼1) and other reasons (n¼2).
Each patient was assessed by a psychiatrist, using the struc-
tured clinical interview M.I.N.I. (Sheehan et al., 1998). All patients
had an ongoing depressive episode of moderate severity (median
duration 11.5 months), within recurrent MDD (Table 1). Themedian MADRS score was 25.5, range 20–35. Comorbidity was
found in two patients, one patient suffering from social phobia and
another patient having both social phobia and generalized anxiety
disorder. Except for psychiatric history, the patients were essen-
tially healthy, according to medical history, physical examination,
blood analysis and magnetic resonance imaging of the brain. The
ongoing episode had not been treated prior to inclusion in the
study. For the patients with previous psychopharmacological
treatment for MDD the medication free period was on average
5.2 years (range 1–10 years). The patients were unmedicated, ex-
cept for one female patient who was treated with 50 mg daily of
the selective β1-adrenoceptor antagonist metoprolol. Half of the
patients had a family history of major depressive disorder. One
patient withdrew from the study, after experiencing panic during
the PET examination, which had to be interrupted. Ten patients
fulﬁlled the study according to protocol.
Control subjects matched for gender and age (73 years) were
recruited from either advertisements in a newspaper or from a
web site for scientiﬁc volunteers. The data from four of the con-
trols has originally been published as part of a case-control study
of Parkinson's disease (Varrone et al., 2014). The controls had no
previous psychiatric history, and were mentally healthy based on a
structured clinical interview performed by a psychiatrist (M.T.)
using either M.I.N.I. (n¼6) or the Structured Clinical Interview for
the Diagnostic and Statistical Manual of Mental Disorders (Fourth
Edition) (n¼4). Except from further psychiatric assessment, the
controls underwent the same examinations as the patients in the
study.
2.2. Magnetic resonance imaging
For one of the patients and four of the controls MRI examina-
tions were performed with 1.5T (GE Signa). Nine patients and six
controls were examined with a 3T system (GE Signa). The reason
for the different MRI equipment in the study was an upgrade of
the MR system at the Karolinska Hospital MR centre. The MRI
protocol included a T1-weighted 3-dimensional sequence for
coregistration with PET images and a T2-weighted sequence to
rule out pathology.
2.3. Positron emission tomography – experimental procedure
At the day of the PET examination the patients were assessed
by a psychiatrist (M.T.) applying MADRS and the Clinical Global
Impression scale-Severity (CGI-S (Guy, (1976)), to estimate the
severity of the depression at time of PET. As a validation, the
Fig. 2. Binding potential (BPND) in the ACC in MDD patients (right) compared with
controls (left). Error bars indicate standard error of the mean.
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(Svanborg and Asberg, 2001). Urine analysis for drug screening for
metamphetamine, cocaine, cannabis, bensodiazepines, metha-
done, barbiturates, amphetamine, opiates, phencyclidine and bu-
prenorphine was performed in all subjects before the PET mea-
surement, to exclude the use of drugs at time of PET. In each PET
measurement the subject was placed recumbent with the head in
the gantry of the PET system. A head ﬁxation system with an in-
dividual plaster helmet was used (Bergstrom et al., 1981).
[11C]AZ10419369 was synthesized from its desmethyl precursor as
previously described (Andersson et al., 2011). [11C]AZ10419369 in
a sterile physiological phosphate buffer (pH 7.4) solution was di-
luted with saline to the volume of 10 ml and then injected as a
bolus within 10 s into a cannula inserted into an antecubital vein.
The cannula was then immediately ﬂushed with 10 ml saline. Each
subject was examined with PET and the radioligand
[11C]AZ10419369. The PET system used was ECAT HRRT (High
Resolution Research Tomograph, Siemens Molecular Imaging)
with a spatial resolution of approximately 1.5 mm in the centre
and 2.4 mm at 10 cm off-centre full-width at half maximum with
the current protocol (Varrone et al., 2009). List mode data were
acquired for 93 min. Images were reconstructed in a series of 37
frames of increasing duration (810 s, 520 s, 430 s, 460 s,
4180 s, 12360 s) using the ordinary Poisson 3D ordered subset
expectation maximization algorithm, with 10 iterations and 16
subsets, including modeling of the system resolution (Varrone
et al., 2009).
2.4. Image analysis
For eight of the patients and nine of the controls the PET
images were corrected for head motion with a frame-to-frame-
realignment algorithm as previously described (Schain et al.,
2012). The head movements of two of the patients and one of the
controls exceeded the limits of this method and their PET images
were hence reconstructed using frame speciﬁc attenuation-data,
according to a procedure described earlier (Tiger et al., 2014).
T1-weighted (T1-w) MRI-images were coregistered to PET-
images and segmented into grey matter, white matter and cere-
brospinal ﬂuid using SPM5 (Statistical Parametric Mapping, Well-
come Trust Centre for Neuroimaging, U.K.). The PET data were
corrected for partial volume effects (PVE) according to the method
developed by Meltzer et al. (1990). PVE correction was performed
using an in-house script implemented in MATLAB, as previously
described (Schain et al., 2012). The analysis of PET data was basedFig. 1. Saggital view of MR image of an individual subject, with the ACC ROI in red
and the SGPF ROI in light blue. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)on regions of interest (ROIs). Eight ROIs were chosen based on
relevance for the pathophysiology of MDD according to the lit-
erature and the previous case-control PET study of 5-HT1B re-
ceptors in MDD (Drevets, 2000; Murrough et al., 2011; Savitz and
Drevets, 2013): orbitofrontal cortex, anterior cingulate cortex
(ACC), subgenual prefrontal cortex(SGPFC), amygdala, hippo-
campus, ventral striatum, pallidum and dorsal brain stem (DBS),
and for reference cerebellum. The ROIs were deﬁned manually on
the MR images as previously described (Varnas et al., 2011), except
DBS and SGPFC. The DBS ROI was deﬁned to include especially the
median raphe nuclei, by delineation of the dorsal half of the
brainstem on 5 consecutive horizontal MR sections ranging from
the lower limit of the inferior colliculi to the isthmus (Kranz et al.,
2012; Tiger et al., 2014). SGPFC was deﬁned as described by Dre-
vets et al., (Drevets et al., 1997). The SGPFC ROI was thus located
adjacent and ventral to the ACC ROI, without overlap between the
two ROIs (Fig. 1). Volumes of the ROIs delineated on MR images
were acquired with SPM5, and the ROI volumes of the patients
were compared with those of the controls. BPND values were cal-
culated with the simpliﬁed reference tissue model (SRTM) (Lam-
mertsma and Hume, 1996), implemented in Matlab R2007b for
Windows. The cerebellum was chosen as reference region, due to
its negligible 5-HT1B receptor density (Varnas et al., 2001).
2.5. Statistical analysis
The regional BPND-values obtained from the PET measurements
and the volumes of the manually deﬁned ROIs of the patients were
compared with those of the matched controls using independent
t-tests, with two-tailed p-values. BPND statistics was not corrected
for multiple comparisons. Correlations between [11C]AZ10419369
BPND and age and MADRS were examined using Pearson's corre-
lation. Group*age interactions were tested for with two-way AN-
OVA. The statistical analyses were conducted using IBM SPSS
Statistics 22 for Windows (SPSS Inc, Somers, NY, USA).3. Results
Demographic characteristics for the patients and controls are
presented in Table 1. Ten out of the 11 patients and 10 matched
controls completed the study according to protocol. After in-
travenous injection of [11C]AZ10419369, there was a rapid increase
in brain radioactivity with higher radioactivity in brain regions
known to contain the 5-HT1B receptor (Table 1, Supplementary
ﬁgure).
When compared with controls [11C]AZ10419369 binding was
20% lower in the anterior cingulate cortex in depressed patients
(p¼0.013) (Fig. 2, Table 2). In the subgenual prefrontal cortex the
Table 2
Mean regional [11C]AZ10419369 binding potential values.
ROI Controls BPND7SD Patients BPND7SD p Controls V (ml)7SD Patients V (ml)7SD p
OFC 1.4970.15 1.2770.37 0.096 13.6572.83 12.4671.12 0.230
ACC 1.3870.22 1.1070.22 0.013* 3.2370.69 3.1070.84 0.705
SGPFC 1.2270.17 1.0270.21 0.026* 0.7570.22 0.7370.18 0.864
Ventral striatum 1.9870.34 1.7070.45 0.126 2.1770.39 2.2470.50 0.730
Pallidum 3.3370.56 3.0470.66 0.302 1.2370.14 1.2370.19 0.989
Amygdala 1.0670.21 0.9670.38 0.463 1.1970.11 1.2270.17 0.663
Hippocampus 0.4870.12 0.3370.13 0.012* 3.3170.33 3.9270.48 0.004**
DBS 0.5570.28 0.7070.28 0.240 1.1870.13 1.1570.26 0.779
V¼Volume, OFC¼Orbitofrontal cortex, ACC¼Anterior cingulate cortex, SGPFC¼Subgenual prefrontal cortex, DBS¼Dorsal brain stem, SD¼Standard Deviation.
** ¼po0.005,
* ¼po0.05.
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(p¼0.026). The largest difference was found in the hippocampus,
with 32% lower [11C]AZ10419369 binding in the depressed pa-
tients (p¼0.012). For other regions in the brain, including the
ventral striatum and pallidum, there were no signiﬁcant differ-
ences in BPND between patients and controls. The average BPND in
the whole brain was lower for the patients than for the controls
(0.81 versus 1.01, p¼0.043).
The hippocampus region was larger in the patients than in the
controls (3.92 ml versus 3.31 ml, p¼0.001) (Table 2). The BPND in
hippocampus remained low in the MDD patients, also when ad-
justing for differences in ROI volumes (0.33 versus 0.58, p¼0.001).
There were no signiﬁcant volume differences for any of the other
examined brain regions.
For the whole brain [11C]AZ10419369 binding correlated ne-
gatively with age for the patients(p¼0.894, po0.001), but not
for the controls(p¼0.473, p¼0.168). At a regional level,
[11C]AZ10419369 BPND in ACC, SGPFC, and hippocampus correlated
inversely with age for the patients (p¼0.621 in ACC, p¼0.003,
p¼0.673, p¼0.033 in SGPFC, p¼0.846, p¼0.002 in hippo-
campus). There was no evidence of signiﬁcant age*group interac-
tion for BPND in ACC (p¼0.333), HIP p¼0.143), SGPFC (p¼0.181) or
whole brain (p¼0.357). MADRS scores did not correlate with BPND
in ACC (p¼0.83, p¼0.819), SGPFC (p¼0.137, p¼0.706) or
hippocampus (p¼0.144, p¼0.692).4. Discussion
The main ﬁnding in this study was lower [11C]AZ10419369
binding to the 5-HT1B receptor in the anterior cingulate cortex in
patients with MDD when compared with controls. The BPND was
also low in the hippocampus and in the subgenual prefrontal
cortex in MDD patients, whereas there were no signiﬁcant differ-
ences in the other examined brain regions.
Several lines of research point to the importance of the anterior
cingulate cortex in the pathophysiology of MDD. At physiological
conditions, the rostral anterior cingulate cortex is involved in
emotional regulation, related to motivation and assignment of
emotional valence to stimuli (Bush et al., 2000; Devinsky et al.,
1995). In functional PET studies of healthy volunteers, it has been
reported that cerebral blood ﬂow in the subgenual anterior cin-
gulate cortex is increased during sad mood (George et al., 1995;
Mayberg et al., 1999). In a meta-analysis of functional imaging
studies of the neuroanatomy of emotion sadness was over twice as
frequently reported as any other emotion during activation of the
subgenual anterior cingulate cortex (Phan et al., 2002). Pre- and
subgenual parts of the anterior cingulate cortex regulate negative
emotional responses (Etkin et al., 2011). In clinical fMRI studies
abnormal activity in the ACC in subjects with MDD has been acommon ﬁnding (Steele et al., 2007). In case-control studies using
[18F]FDG-PET, increased metabolism in the subgenual anterior
cingulate cortex in MDD has been reported (Drevets et al., 2008b).
These ﬁndings have contributed to the rational for reversible le-
sioning of the subgenual anterior cingulate cortex with deep brain
stimulation, a treatment which indeed has shown antidepressive
effects (Mayberg et al., 2005). Moreover, cingulotomy, inducing a
lesion in the ACC, has since many years been used for treatment of
patients with chronic refractory depression (Steele et al., 2008).
Thus, the present study adds to a line of evidences implicating a
role for the anterior cingulate cortex in MDD.
The lower [11C]AZ10419369 BPND found in the ACC in depressed
patients compared with controls might reﬂect either higher ser-
otonin concentration or lower 5-HT1B receptor density. Low
5-HT1B receptor density in the ACC of patients with MDD would be
in line with the low mRNA concentration of the functionally re-
lated protein p11 reported for the ACC in patients suffering from
MDD (Svenningsson et al., 2006). The multifunctional protein p11
has a proposed role in the pathophysiology of MDD and in re-
sponse to antidepressants (Svenningsson et al., 2013). Early re-
duction of p11 in natural killer cells and monocytes with SSRI
treatment has been found to correlate with antidepressant re-
sponse in patients with MDD (Svenningsson et al., 2014). p11
knockout in mice has resulted in a depressive phenotype with
reduced numbers of 5-HT1B receptors at the cell membrane
(Svenningsson et al., 2006). The view that 5-HT1B receptor ex-
pression in the cell membrane is dependent on p11 has received
consistent support from studies using brain tissue from p11 KO
mice as well as immunohistochemistry and in situ hybridization,
and co-expression of 5-HT1B receptors has been demonstrated in
p11 containing cells in the cingulate cortex (Egeland et al., 2011;
Svenningsson et al., 2013). Finally, signiﬁcant correlations between
5-HT1B receptor and p11 mRNA have been found post-mortem in
frontopolar cortex, orbitofrontal cortex and hippocampus in de-
pressed as well as control subjects (Anisman et al., 2008). Thus,
low 5-HT1B receptor density in the ACC in depressed patients
would be consistent with the previous ﬁndings of low p11 mRNA
in the ACC in MDD (Svenningsson et al., 2006). Alternatively, the
low [11C]AZ10419369 BPND found in the ACC in MDD could reﬂect
high serotonin concentration. Sensitivity to endogenous serotonin
levels has been demonstrated for [11C]AZ10419369 in non-human
primates, after challenges with fenﬂuramine (Finnema et al., 2010)
or supratherapeutic doses of the selective serotonin reuptake in-
hibitor escitalopram (Nord et al., 2013), expected to yield a marked
increase of extracellular serotonin in brain. The lower regional
BPND may thus be explained by a higher synaptic concentration of
serotonin in MDD compared to control subjects. However, this
interpretation does not ﬁnd support in post mortem data. In two
studies of serotonin concentration in brain of depressed suicide
victims and controls there was no elevation of the serotonin
M. Tiger et al. / Psychiatry Research: Neuroimaging 253 (2016) 36–4240concentration in cortical regions or hippocampus (Cheetham et al.,
1989; Owen et al., 1986). Although high synaptic serotonin con-
centration cannot be ruled out, we ﬁnd it more likely that the low
[11C]AZ10419369 BPND in the ACC of the examined depressed pa-
tients reﬂects low 5-HT1B receptor density. Importantly, irrespec-
tive of whether the ﬁndings reﬂect high serotonin concentration
or low 5-HT1B receptor density, our results support the current
hypothesis on a role for serotonergic neurotransmission in the
anterior cingulate cortex in the pathophysiology of MDD (Drevets
et al., 2008a; Mayberg, 1997).
In our previous study we found no signiﬁcant change in
[11C]AZ10419369 BPND in the ACC with psychotherapy for de-
pression (Tiger et al., 2014). A possible interpretation of this
ﬁnding is that the low BPND in the ACC is a vulnerability trait for
developing depression, rather than a result of the depressive state.
All the examined patients in this study had recurrent depressive
episodes. The reduced BPND in the ACC could also be a con-
sequence of the major depressive disorder itself, since it was found
irrespective of family history for depression. However, there was
no signiﬁcant correlation between [11C]AZ10419369 BPND in the
ACC and the number of depressive episodes (p¼0.785). However,
to better investigate this a broader range of MDD patients, in-
cluding patients with ﬁrst episodes and patients in remission,
must be investigated.
The [11C]AZ10419369 BPND in the depressed patients was low
also for the hippocampus, another region of interest in the pa-
thophysiology of MDD and functionally related to ACC. This is in
analogy with a previous post mortem study on 5-HT1B receptors in
MDD, with low 5-HT1B receptor mRNA in the hippocampus in
depressed female suicide victims compared with controls (Anis-
man et al., 2008). Low 5-HT1B receptor binding in the hippo-
campus would be in line with the low 5-HT1A receptor binding in
this region reported in previous case-control studies of MDD with
PET and [11C]WAY-100635 (Drevets et al., 2007; Savitz and Drevets,
2013). Albeit functionally similar, these two 5-HT1 receptors are
expressed on different hippocampal neurons, with 5-HT1A re-
ceptors being postsynaptical heteroreceptors and 5-HT1B receptors
mainly presynaptical autoreceptors (Riad et al., 2000; Sari, 2004),
and in different cortical layers (Laurent et al., 2002; Meunier et al.,
2013; Riad et al., 2000). A more detailed understanding of ser-
otonergic innervation of the hippocampus is required to build a
uniﬁed model capturing these observations.
In contrast with the previously published PET study on 5-HT1B
receptor binding in MDD (Murrough et al., 2011) we found no
signiﬁcant difference in BPND in the ventral striatum or pallidum.
In that study, Murrough and coworkers used a different radi-
oligand, [11C]P943, and reported results from a single ROI, “ventral
striatum/ventral pallidum”, but no data were provided for the ROIs
showing aberrations in the present study. The patient cohort in
the study by Murrough et al. is similar to ours, with unmedicated
patients with recurrent MDD, with a relatively long duration of the
current episode (9.4 versus 11.5 months) and similar wash-out
period (4 weeks versus 1 month). The patient sample in the
[11C]P943 study of MDD differs from ours in the following aspects:
higher proportion of drug-naïve patients (nine versus four out of
ten), patients were over-weight, bordering on obese (average BMI
29.7 versus 23.4 in our patient sample) and smokers were in-
cluded. It is not clear whether any of these differences could ex-
plain the 5-HT1B receptor binding discrepancy found in the ventral
striatum and pallidum in the two PET studies of 5-HT1B receptors
in the brain in MDD.
The average whole brain [11C]AZ10419369 BPND was lower in
the MDD patients than in the controls. It could be argued that
there may have been a change in the serotonergic neuro-
transmission in the raphe nuclei in the MDD group, which has
affected the brain globally. Indeed, there was higher BPND in theDBS in the MDD patients, which could reﬂect higher BPND in
especially the median raphe nucleus, that theoretically would
lower serotonin release in serotonergic projection areas (Schlicker
et al., 1997). This would harmonize with the distinct BPND reduc-
tion in the DBS after psychotherapy for MDD that we have pre-
viously reported (Tiger et al., 2014). However, the difference in DBS
BPND between MDD patients and controls was not signiﬁcant.
Further research with optimized delineation of the rostral raphe
nuclei is needed to determine the effect of MDD on 5-HT1B re-
ceptor binding in the raphe nuclei.
The sample size in the present molecular imaging study of
unmedicated patients with recurrent major depressive disorder
was small, although comparable with earlier PET studies (Mur-
rough et al., 2011; Savitz and Drevets, 2013). To avoid the risk of
type II errors inherent with this limited statistical power and ex-
pected interindividual variation and to reduce chance ﬁndings by
repeated testing, the controls were matched carefully with their
patients and the analysis hypothesis driven.
The speciﬁc radioactivity was higher in the MDD patients
compared with the controls. If the speciﬁc radioactivity would
have been low, the injected mass needed to obtain the radio-
activity dose would have been high. This could have led to a mass
effect, with displacement of radioligand binding by unlabeled
compound. However, given the low masses injected in this study,
mass effects are unlikely. Furthermore, there was no signiﬁcant
difference in injected mass between MDD patients and controls.
A potential issue in this study is the use of two different MRI
scanners, with 1.5 or 3 T magnetic ﬂux density respectively. To
minimize the consequence of this difference we deﬁned the ROIs
manually. Reduced volume in the subgenual prefrontal cortex and
the hippocampus is a replicated ﬁnding in major depressive dis-
order (Drevets, 1998; Hajek et al., 2008; Rodriguez-Cano et al.,
2014). Less grey matter in the ACC would in theory correspond to
fewer synapses and therefore reduced 5-HT1B receptor binding
potential. However, there were no signiﬁcant differences in grey
matter volumes in the ACC or SGPFC ROIs between depressed
patients and controls. To our surprise, the hippocampal ROI vo-
lume was greater in the patients than in the controls. Reduced
hippocampal volumes have been reported in volumetric MRI stu-
dies of depression (Arnone et al., 2013; Zhao et al., 2014). However,
in a post-mortem material no differences in hippocampal volumes
between depressed patients and controls were found (Bielau et al.,
2013). Moreover, the hippocampus is a plastic brain structure, with
a clear association between volume and education level (Janowitz
et al., 2014). There was a trend towards a higher education level in
the patients than in the controls in our study (16.4 versus 14.6
years), although this was not signiﬁcant (p¼0.169). Importantly,
when adjusting BPND for volume the difference in hippocampal
binding between the MDD patients and the controls becomes even
more distinct (44% lower BPND in MDD patients, p¼0.001). Fur-
thermore, the PET data were corrected for partial volume effects.
Hence, reduced volume cannot explain the low [11C]AZ10419369
binding found in the ACC and associated regions in patients with
MDD.
In conclusion, 5-HT1B receptor binding in the ACC was low in
patients with recurrent MDD when compared with controls. The
ﬁnding corroborates the previously proposed role for ACC in the
pathophysiology of recurrent MDD. Further studies are needed to
determine if the lower 5-HT1B receptor binding in the ACC is a
vulnerability trait for developing depression or may be related to
the depressive state itself.
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